Program
All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.
Thursday, October 5
Friday, October 6
Plenary Session 1: Tumor Microenvironment and Immune Oncology I
Proffered Talks I
Plenary Session 2: Rare Ovarian Tumors
Plenary Session 3: Drug Discovery, Development, and Novel Pathways
Plenary Session 4: Early Detection and Prevention
Saturday, October 7
Plenary Session 5: Epigenetics and Epitranscriptomics
Keynote Lecture II
Proffered Talks II
Plenary Session 6: Tumor Microenvironment and Immune Oncology II
Thursday, October 5
Welcome and Opening Keynote
5-6 P.M.
Welcome from Conference Cochairs
Opening Keynote
David D.L. Bowtell, Peter MacCallum Cancer Center, Victoria, Australia
Break
6-6:30 P.M.
Poster Session A/Opening Reception
6:30-8 P.M.
Friday, October 6
Continental Breakfast
7-8 A.M.
Plenary Session 1: Tumor Microenvironment and Immune Oncology I
8-10 A.M.
Fallopian tube precursors make tumors nervous
Ronny I. Drapkin, University of Pennsylvania, Philadelphia, Pennsylvania
Regional combating of immunosuppressive forces in the ovarian tumor microenvironment
Daniel J. Powell Jr., University of Pennsylvania, Philadelphia, PA
Friend or foe: Reevaluating the therapeutic potential of monocytes and tumor-associated macrophages in ovarian cancer Oladapo O. Yeku, Massachusetts General Hospital, Boston, MA
Two short talks selected from proffered abstracts
Break
10-10:15 A.M.
Proffered Talks I
10:15-11:15 A.M.
Lunch (On Own)
11:45 A.M.-12:45 P.M.
Plenary Session 2: Rare ovarian tumors
12:45-2:15 P.M.
Tumor heterogeneity of ovarian clear cell carcinoma
Ruby Yun-Ju Huang, National Taiwan University, Teipei, Taiwan
Title to be announced
David G. Huntsman, University of British Columbia, Vancouver, BC, Canada
Epigenetic approaches for endometriosis-associated ovarian cancer
Rugang Zhang, MD Anderson Cancer Center, Houston, Texas
Break
2:15-2:30 P.M.
Plenary Session 3: Drug Discovery, Development, and Novel Pathways
2:30-4:30 P.M.
Latest developments in targeting the DNA damage response in the clinic
Timothy A. Yap, MD Anderson Cancer Center, Houston, Texas
Advancing novel therapeutics through reverse translation
Sarah F. Adams, University of New Mexico, Albuquerque, New Mexico
Targeting AXL in platinum-resistant ovarian cancer: From the lab bench to Phase 3 trial
Katherine C. Fuh, University of California San Francisco, San Francisco, California
Cell cycle checkpoint pathways as therapeutic target
Jung-min Lee, National Cancer Institute, Bethesda, Maryland
Break
4:30-5 P.M.
PLENARY SESSION 4: Early Detection and Prevention
5-7 P.M.
Improving targeted precision prevention in ovarian cancer
Ranjit Manchanda, Barts Cancer Institute, Queen Mary University of London, London, England
Is salpingectomy as effective as bilateral salpingo-oophorectomy in preventing ovarian, fallopian tube, and peritoneal cancer? Let’s prove it!
Kathryn P. Pennington, University of Washington, Seattle, Washington
Opportunistic salpingectomy for ovarian cancer prevention
Gillian Hanley, University of British Columbia, Vancouver, BC, Canada
AI-enabled liquid biopsy for ovarian cancer detection
Daniel A. Heller, Memorial Sloan Kettering Cancer Center, New York, New York
Poster Session B/Reception
7-8:30 P.M.
Saturday, October 7
Continental Breakfast
7-8 A.M.
Plenary Session 5: Epigenetics and Epitranscriptomics
8-10 A.M.
FTO-regulated m6A modifications in ovarian cancer
Daniela E. Mattei, Northwestern University, Chicago, Illinois
Title to be announced
Kate Lawrenson, Cedars-Sinai Medical Center, Los Angeles, California
Targeting transposable elements with epigenetic modulators to reverse ovarian cancer immune evasion
Katherine B. Chiappanelli, The George Washington University School of Medicine and Health Sciences, Washington D.C.
Two short talks selected from proffered abstracts
Break
10-10:30 A.M.
Keynote Lecture II
10:30-11:15 A.M.
Kathleen R. Cho, University of Michigan Medical School, Ann Arbor, Michigan
Proffered Talks II
11:15 A.M.-12:15 P.M.
Extended Break
12:15-1:00 P.M.
Plenary Session 6: Tumor Microenvironment and Immune Oncology II
12:45-2:15 P.M.
B cells: the immune system’s secret weapon against ovarian cancer
Brad Nelson, University of British Columbia, Vancouver, BC, Canada
Spatial multiomics allows identifying the genomic and proteomic changes from borderline to low-grade serous cancer
Ernst R. Lengyel, University of Chicago, Chicago, Illinois
Mutational processes as determinants of immune evasion in ovarian cancer
Sohrab Shah, Memorial Sloan Kettering Cancer Center, New York, New York
Two short talks selected from proffered abstracts